by support | Nov 28, 2022 | Uncategorized
The voice of the patient has a role in the drug development and approval process. In fact, recent legislation mandates an increased emphasis on incorporating the patient perspective into the drug approval process.
by support | Nov 28, 2022 | Uncategorized
Our continuing education-accredited conference is a groundbreaking opportunity for health care providers, researchers, patients, families, and caregivers to learn about the latest advances in research, treatment, and care from leaders in the field of nontuberculous...
by support | Nov 28, 2022 | Uncategorized
ARIKAYCE® is currently the only FDA approved drug designed specifically for NTM (MAC) and now available through prescription from your physician for treatment of refractory MAC lung infection in adult patients. This medication is only available through select...
by support | Nov 28, 2022 | Uncategorized
Every day, NTM Info & Research’s commitment to finding therapies serves as hope for the NTM community. We are constantly looking for ways to boost our financial support of research to achieve better treatments and, eventually, a cure. Until that cure is found, we...
by support | Nov 28, 2022 | Uncategorized
On April 8th, 2019 the U.S. Food & Drug Administration will host a public workshop on the development of antibacterial drugs for the treatment of nontuberculous mycobacterial (NTM) infection.
by support | Nov 28, 2022 | Uncategorized
The FDA workshop on “The Development of Antibiotics for the Treatment of NTM Disease” on April 8, 2019 was very successful, with more than 100 people attending in person. The agenda focused on issues surrounding clinical trials and the development of a validated...
